In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Resolvyx Pharmaceuticals Inc.

Latest From Resolvyx Pharmaceuticals Inc.

Warp Drive Bio revises senior management

Dr Gregory Verdine

Celtic finalises deal to move Resolvyx' dry eye treatment through Phase III

Celtic Therapeutic Holdings, the global private equity firm, has finalised an exclusive option deal announced in October with Resolvyx Pharmaceuticals to further develop a RX-10045, a late-stage topical eye-drop that has shown potential for treating dry eye syndrome and other ophthalmic conditions. Under the terms of the deal, Celtic has acquired and licensed worldwide rights to RX-10045 in exchange for up-front consideration, near-term milestone payments, and funding for 100% of future development costs (details of all of which were undisclosed).

Orthopedics Respiratory

Deals Shaping the Medical Industry (12/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions

Celtic targets eye indications, continues fundraising

Celtic Therapeutics Holdings, the global private equity firm, has made its fourth investment by committing an undisclosed amount for an exclusive option from Resolvyx Pharmaceuticals to acquire and license rights to RX-10045 for all ophthalmic conditions. In connection with the deal, Celtic has bought a note convertible into Resolvyx equity. Meanwhile, Celtic is also putting the final touches to a "substantial" final closing of its current fund.

Metabolic Disorders Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Resolvyx Pharmaceuticals Inc.
  • Senior Management
  • Per Gjorstrup, MD, PhD, CMO
    Greg Weinhoff, MD, Exec. Chmn.
  • Contact Info
  • Resolvyx Pharmaceuticals Inc.
    Phone: (781) 541-5045
    222 3rd St.
    Ste. 1100
    Cambridge, MA 02142